BALAXI PHARMACEUTICALS
Quarterly Results Analysis [Dec2024]
BALAXI PHARMACEUTICALS Quarterly Results
Consolidated | Dec2024 UnAudited |
Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 Audited |
Sep2023 Audited |
Jun2023 UnAudited |
Mar2023 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹73 Cr | ₹77 Cr | ₹66 Cr | ₹60 Cr | ₹61 Cr | ₹55 Cr | ₹66 Cr | ₹81 Cr |
Expenses | ₹69 Cr | ₹67 Cr | ₹56 Cr | ₹46 Cr | ₹47 Cr | ₹44 Cr | ₹57 Cr | ₹68 Cr |
Operating Income | ₹4 Cr | ₹11 Cr | ₹10 Cr | ₹13 Cr | ₹14 Cr | ₹11 Cr | ₹9 Cr | ₹13 Cr |
Other Income | ₹4 Cr | ₹-4 Cr | ₹-2 Cr | ₹-2 Cr | ₹0 Cr | ₹0 Cr | ₹-1 Cr | ₹0 Cr |
Interest | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
Depreciation | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹1 Cr |
Profit Before Tax | ₹6 Cr | ₹6 Cr | ₹7 Cr | ₹11 Cr | ₹14 Cr | ₹16 Cr | ₹-39 Cr | ₹11 Cr |
Profit After Tax | ₹5 Cr | ₹5 Cr | ₹6 Cr | ₹11 Cr | ₹14 Cr | ₹14 Cr | ₹-41 Cr | ₹8 Cr |
EPS | ₹0.97 | ₹0.83 | ₹1.17 | ₹2.01 | ₹13.29 | ₹2.82 | ₹-8.08 | ₹1.59 |
Industry Peers & Returns | 1W | 1M | 1Y |
BALAXI PHARMACEUTICALS | -1.8% | 25% | -34.6% |
ADANI ENTERPRISES | 0.7% | 10.7% | -25.6% |
REDINGTON | -5.9% | -8.5% | 18.5% |
MMTC | 0.6% | 6.1% | -21.5% |
HONASA CONSUMER | -1.4% | 4.7% | -41.4% |
LLOYDS ENTERPRISES | 9.8% | 1.7% | 57.9% |
ENTERO HEALTHCARE SOLUTIONS | 2.2% | -7.8% | 13.7% |
OPTIEMUS INFRACOM | 0.4% | -5.5% | 65.9% |
POLO QUEEN INDUSTRIAL & FINTECH | -14.3% | -49.8% | 36.1% |
BALAXI PHARMACEUTICALS Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -5.29 % |
Y-o-Y | 20.57 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Dec2024 | ₹73 Cr | -5.29 | |
Sep2024 | ₹77 Cr | 17.92 | |
Jun2024 | ₹66 Cr | 9.68 | |
Mar2024 | ₹60 Cr | -1.57 | |
Dec2023 | ₹61 Cr | 11.08 | |
Sep2023 | ₹55 Cr | -17.03 | |
Jun2023 | ₹66 Cr | -18.25 | |
Mar2023 | ₹81 Cr | - |
BALAXI PHARMACEUTICALS Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | -62.34 % |
Y-o-Y | -70.81 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Dec2024 | ₹4 Cr | -62.34 | |
Sep2024 | ₹11 Cr | 4.97 | |
Jun2024 | ₹10 Cr | -25.11 | |
Mar2024 | ₹13 Cr | -1.41 | |
Dec2023 | ₹14 Cr | 26.90 | |
Sep2023 | ₹11 Cr | 21.76 | |
Jun2023 | ₹9 Cr | -30.63 | |
Mar2023 | ₹13 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -60.23 % |
Y-o-Y | -75.79 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Dec2024 | 5.44% | -60.23 | |
Sep2024 | 13.68% | -11.00 | |
Jun2024 | 15.37% | -31.72 | |
Mar2024 | 22.51% | 0.18 | |
Dec2023 | 22.47% | 14.23 | |
Sep2023 | 19.67% | 46.79 | |
Jun2023 | 13.4% | -15.19 | |
Mar2023 | 15.8% | - |
BALAXI PHARMACEUTICALS Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | 16.87 % |
Y-o-Y | -60.56 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Dec2024 | ₹5 Cr | 16.87 | |
Sep2024 | ₹5 Cr | -29.20 | |
Jun2024 | ₹6 Cr | -40.74 | |
Mar2024 | ₹11 Cr | -19.57 | |
Dec2023 | ₹14 Cr | -5.78 | |
Sep2023 | ₹14 Cr | Positive | |
Jun2023 | ₹-41 Cr | Negative | |
Mar2023 | ₹8 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | 23.44 % |
Y-o-Y | -67.26 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Dec2024 | 7.32 % | 23.44 | |
Sep2024 | 5.93 % | -39.92 | |
Jun2024 | 9.87 % | -45.98 | |
Mar2024 | 18.27 % | -18.29 | |
Dec2023 | 22.36 % | -15.21 | |
Sep2023 | 26.37 % | Positive | |
Jun2023 | -62.68 % | Negative | |
Mar2023 | 10.04 % | - |
BALAXI PHARMACEUTICALS Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | 16.87 % |
Y-o-Y | -92.70 % |
Quarters | EPS | % Change | |
---|---|---|---|
Dec2024 | ₹0.97 | 16.87 | |
Sep2024 | ₹0.83 | -29.06 | |
Jun2024 | ₹1.17 | -41.79 | |
Mar2024 | ₹2.01 | -84.88 | |
Dec2023 | ₹13.29 | 371.28 | |
Sep2023 | ₹2.82 | Positive | |
Jun2023 | ₹-8.08 | Negative | |
Mar2023 | ₹1.59 | - |
You may also like the below Video Courses
ADANI ENTERPRISES LTD vs REDINGTON LTD vs MMTC LTD
HONASA CONSUMER LTD vs LLOYDS ENTERPRISES LTD vs ENTERO HEALTHCARE SOLUTIONS LTD